Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications

Breast Cancer Research and Treatment

Volumn 158, Issue 2, 2016, Pages 219-232

  Veeraraghavan, Jamunarani ^a   Ma, Jiacheng ^a   Hu, Yiheng ^a   Wang, Xiao Song ^a,b,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Bioinformatics; Breast cancer; Genomics; Next generation sequencing; Recurrent gene fusions; Tumorigenesis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; TRANSCRIPTION FACTOR YAP1;

ARID1A MAST2 GENE; BCAS4 AURKA GENE; BREAST CANCER; COMPARATIVE GENOMIC HYBRIDIZATION; CTSD IFITM10 GENE; EEFIDP3 FRY GENE; ERLIN2 FGFR1 GENE; ESR1 CCDC170 GENE; ESR1 YAP1 GENE; ETV6 NTRK3 GENE; FGFR2 AFF3 GENE; FGFR2 CASP7 GENE; FGFR2 CCDC6 GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DUPLICATION; GENE FUNCTION; GENE FUSION; GENE IDENTIFICATION; GENE REARRANGEMENT; GENE SILENCING; GENETIC TRANSCRIPTION; GPBP1L1 MAST2 GENE; HUMAN; MAGI3 AKT3 GENE; NEXT GENERATION SEQUENCING; NFIX MAST1 GENE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA SEQUENCE; RPS6KB1 VMP1 GENE; SCNN1A TNFRSF1A GENE; SEC16A NOTCH1 GENE; SEC22B NOTCH2 GENE; SEQUENCE ANALYSIS; SLC2A1 FAF1 GENE; TADA2A MAST1 GENE; ZNF700 MAST1 GENE; BREAST TUMOR; DNA SEQUENCE; FEMALE; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION; GENETICS; GENOMICS; HIGH THROUGHPUT SEQUENCING; PATHOLOGY; PROCEDURES;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE FUSION; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; SEQUENCE ANALYSIS, DNA;

EID: 84976509420     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-016-3876-y     Document Type: Review

References (82)

1. Mitelman F, Johansson B, Mertens F (2007) The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer 7(4):233–245. doi:10.1038/nrc2091
2. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, Rahman N, Stratton MR (2004) A census of human cancer genes. Nat Rev Cancer 4(3):177–183. doi:10.1038/nrc1299
3. Ren R (2005) Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 5(3):172–183. doi:10.1038/nrc1567
4. Goldman JM, Melo JV (2003) Chronic myeloid leukemia–advances in biology and new approaches to treatment. New Engl J Med 349(15):1451–1464. doi:10.1056/NEJMra020777
5. de Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D, Spurr NK, Heisterkamp N, Groffen J, Stephenson JR (1982) A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 300(5894):765–767
6. Kumar-Sinha C, Kalyana-Sundaram S, Chinnaiyan AM (2015) Landscape of gene fusions in epithelial cancers: seq and ye shall find. Gen Med 7:129. doi:10.1186/s13073-015-0252-1
7. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310(5748):644–648. doi:10.1126/science.1117679
8. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448(7153):561–566. doi:10.1038/nature05945
9. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, Lee J, Richards WG, Sugarbaker DJ, Ducko C, Lindeman N, Marcoux JP, Engelman JA, Gray NS, Lee C, Meyerson M, Janne PA (2008) EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14(13):4275–4283. doi:10.1158/1078-0432.CCR-08-0168
10. Robinson DR, Kalyana-Sundaram S, Wu YM, Shankar S, Cao X, Ateeq B, Asangani IA, Iyer M, Maher CA, Grasso CS, Lonigro RJ, Quist M, Siddiqui J, Mehra R, Jing X, Giordano TJ, Sabel MS, Kleer CG, Palanisamy N, Natrajan R, Lambros MB, Reis-Filho JS, Kumar-Sinha C, Chinnaiyan AM (2011) Functionally recurrent rearrangements of the MAST kinase and notch gene families in breast cancer. Nat Med 17(12):1646–1651. doi:10.1038/nm.2580
11. Edwards PA (2010) Fusion genes and chromosome translocations in the common epithelial cancers. J Pathol 220(2):244–254. doi:10.1002/path.2632
12. Mertens F, Johansson B, Fioretos T, Mitelman F (2015) The emerging complexity of gene fusions in cancer. Nat Rev Cancer 15(6):371–381. doi:10.1038/nrc3947
13. Rowley JD, Beau MML, Rabbitts TH (2015) Chromosomal Translocations and Genome Rearrangements in Cancer. Springer International Publishing
14. Malhotra GK, Zhao X, Band H, Band V (2010) Histological, molecular and functional subtypes of breast cancers. Cancer Biol Ther 10(10):955–960
15. Cancer Genome Atlas N (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61–70. doi:10.1038/nature11412
16. Chang M (2012) Tamoxifen resistance in breast cancer. Biomol Ther 20(3):256–267. doi:10.4062/biomolther.2012.20.3.256
17. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med 344(11):783–792. doi:10.1056/NEJM200103153441101
18. Montemurro F, Valabrega G, Aglietta M (2004) Trastuzumab-based combination therapy for breast cancer. Expert Opin Pharmacother 5(1):81–96. doi:10.1517/14656566.5.1.81
19. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20(3):719–726
20. Osborne CK, Schiff R (2011) Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 62:233–247. doi:10.1146/annurev-med-070909-182917
21. Carrara M, Beccuti M, Lazzarato F, Cavallo F, Cordero F, Donatelli S, Calogero RA (2013) State-of-the-art fusion-finder algorithms sensitivity and specificity. BioMed Res Int 2013:340620. doi:10.1155/2013/340620
22. Kumar S, Vo AD, Qin F, Li H (2016) Comparative assessment of methods for the fusion transcripts detection from RNA-Seq data. Sci Rep 6:21597. doi:10.1038/srep21597
23. McCarthy A (2010) Third generation DNA sequencing: pacific biosciences’ single molecule real time technology. Chem Biol 17(7):675–676. doi:10.1016/j.chembiol.2010.07.004
24. English AC, Richards S, Han Y, Wang M, Vee V, Qu J, Qin X, Muzny DM, Reid JG, Worley KC, Gibbs RA (2012) Mind the gap: upgrading genomes with Pacific Biosciences RS long-read sequencing technology. PLoS One 7(11):e47768. doi:10.1371/journal.pone.0047768
25. Kim KS, Peluso P, Hauw E, Sisneros N, Rank D, Badgett MR, Gu JG (2015) Best practices for whole genome de novo sequencing with long-read smrt sequencing. Poster Session Presented at: Genome Technologies—Large Insert Libraries 23rd International Plant and Animal Genome Conference San Diego, CA
26. Leprohon P, Fernandez-Prada C, Gazanion E, Monte-Neto R, Ouellette M (2015) Drug resistance analysis by next generation sequencing in Leishmania. Int J Parasitol Drugs and Drug Resistance 5(1):26–35. doi:10.1016/j.ijpddr.2014.09.005
27. Latysheva NS, Babu MM (2016) Discovering and understanding oncogenic gene fusions through data intensive computational approaches. Nucleic Acids Res. doi:10.1093/nar/gkw282
28. Benelli M, Pescucci C, Marseglia G, Severgnini M, Torricelli F, Magi A (2012) Discovering chimeric transcripts in paired-end RNA-seq data by using ericScript. Bioinformatics 28(24):3232–3239. doi:10.1093/bioinformatics/bts617
29. Liu S, Tsai WH, Ding Y, Chen R, Fang Z, Huo Z, Kim S, Ma T, Chang TY, Priedigkeit NM, Lee AV, Luo J, Wang HW, Chung IF, Tseng GC (2016) Comprehensive evaluation of fusion transcript detection algorithms and a meta-caller to combine top performing methods in paired-end RNA-seq data. Nucleic Acids Res 44(5):e47. doi:10.1093/nar/gkv1234
30. Jia W, Qiu K, He M, Song P, Zhou Q, Zhou F, Yu Y, Zhu D, Nickerson ML, Wan S, Liao X, Zhu X, Peng S, Li Y, Wang J, Guo G (2013) SOAPfuse: an algorithm for identifying fusion transcripts from paired-end RNA-Seq data. Gen Biol 14(2):R12. doi:10.1186/gb-2013-14-2-r12
31. Nicorici D, Satalan M, Edgren H, Kangaspeska S, Murumagi A, Kallioniemi O, Virtanen S, Kilkku O (2014) Fusioncatcher— a tool for finding somatic fusion genes in paired-end RNA-sequencing data. bioRxiv. doi:10.1101/011650
32. Davidson NM, Majewski IJ, Oshlack A (2015) JAFFA: high sensitivity transcriptome-focused fusion gene detection. Gen Med 7(1):43. doi:10.1186/s13073-015-0167-x
33. Zhang J, White NM, Schmidt HK, Fulton RS, Tomlinson C, Warren WC, Wilson RK, Maher CA (2016) INTEGRATE: gene fusion discovery using whole genome and transcriptome data. Gen Res 26(1):108–118. doi:10.1101/gr.186114.114
34. McPherson A, Wu C, Hajirasouliha I, Hormozdiari F, Hach F, Lapuk A, Volik S, Shah S, Collins C, Sahinalp SC (2011) Comrad: detection of expressed rearrangements by integrated analysis of RNA-Seq and low coverage genome sequence data. Bioinformatics 27(11):1481–1488. doi:10.1093/bioinformatics/btr184
35. Chen K, Navin NE, Wang Y, Schmidt HK, Wallis JW, Niu B, Fan X, Zhao H, McLellan MD, Hoadley KA, Mardis ER, Ley TJ, Perou CM, Wilson RK, Ding L (2013) BreakTrans: uncovering the genomic architecture of gene fusions. Gen Biol 14(8):R87. doi:10.1186/gb-2013-14-8-r87
36. Li H, Wang J, Mor G, Sklar J (2008) A neoplastic gene fusion mimics trans-splicing of RNAs in normal human cells. Science 321(5894):1357–1361. doi:10.1126/science.1156725
37. Fernandez-Cuesta L, Sun R, Menon R, George J, Lorenz S, Meza-Zepeda LA, Peifer M, Plenker D, Heuckmann JM, Leenders F, Zander T, Dahmen I, Koker M, Schottle J, Ullrich RT, Altmuller J, Becker C, Nurnberg P, Seidel H, Bohm D, Goke F, Ansen S, Russell PA, Wright GM, Wainer Z, Solomon B, Petersen I, Clement JH, Sanger J, Brustugun OT, Helland A, Solberg S, Lund-Iversen M, Buettner R, Wolf J, Brambilla E, Vingron M, Perner S, Haas SA, Thomas RK (2015) Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data. Gen Biol 16:7. doi:10.1186/s13059-014-0558-0
38. Veeraraghavan J, Tan Y, Cao XX, Kim JA, Wang X, Chamness GC, Maiti SN, Cooper LJ, Edwards DP, Contreras A, Hilsenbeck SG, Chang EC, Schiff R, Wang XS (2014) Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers. Nat Commun 5:4577. doi:10.1038/ncomms5577
39. Wang XS, Prensner JR, Chen G, Cao Q, Han B, Dhanasekaran SM, Ponnala R, Cao X, Varambally S, Thomas DG, Giordano TJ, Beer DG, Palanisamy N, Sartor MA, Omenn GS, Chinnaiyan AM (2009) An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. Nature Biotechnol 27(11):1005–1011. doi:10.1038/nbt.1584
40. Yoshihara K, Wang Q, Torres-Garcia W, Zheng S, Vegesna R, Kim H, Verhaak RG (2015) The landscape and therapeutic relevance of cancer-associated transcript fusions. Oncogene 34(37):4845–4854. doi:10.1038/onc.2014.406
41. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, Lawrence MS, Sivachenko AY, Sougnez C, Zou L, Cortes ML, Fernandez-Lopez JC, Peng S, Ardlie KG, Auclair D, Bautista-Pina V, Duke F, Francis J, Jung J, Maffuz-Aziz A, Onofrio RC, Parkin M, Pho NH, Quintanar-Jurado V, Ramos AH, Rebollar-Vega R, Rodriguez-Cuevas S, Romero-Cordoba SL, Schumacher SE, Stransky N, Thompson KM, Uribe-Figueroa L, Baselga J, Beroukhim R, Polyak K, Sgroi DC, Richardson AL, Jimenez-Sanchez G, Lander ES, Gabriel SB, Garraway LA, Golub TR, Melendez-Zajgla J, Toker A, Getz G, Hidalgo-Miranda A, Meyerson M (2012) Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486(7403):405–409. doi:10.1038/nature11154
42. Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT, Stebbings LA, Leroy C, Edkins S, Mudie LJ, Greenman CD, Jia M, Latimer C, Teague JW, Lau KW, Burton J, Quail MA, Swerdlow H, Churcher C, Natrajan R, Sieuwerts AM, Martens JW, Silver DP, Langerod A, Russnes HE, Foekens JA, Reis-Filho JS, van ‘t Veer L, Richardson AL, Borresen-Dale AL, Campbell PJ, Futreal PA, Stratton MR (2009) Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 462(7276):1005–1010. doi:10.1038/nature08645
43. Kalyana-Sundaram S, Shankar S, Deroo S, Iyer MK, Palanisamy N, Chinnaiyan AM, Kumar-Sinha C (2012) Gene fusions associated with recurrent amplicons represent a class of passenger aberrations in breast cancer. Neoplasia 14(8):702–708
44. Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, Temel JS, Lennes IT, Digumarthy S, Waltman BA, Bast E, Tammireddy S, Morrissey L, Muzikansky A, Goldberg SB, Gainor J, Channick CL, Wain JC, Gaissert H, Donahue DM, Muniappan A, Wright C, Willers H, Mathisen DJ, Choi NC, Baselga J, Lynch TJ, Ellisen LW, Mino-Kenudson M, Lanuti M, Borger DR, Iafrate AJ, Engelman JA, Dias-Santagata D (2011) Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Annals Oncol 22(12):2616–2624. doi:10.1093/annonc/mdr489
45. Kris M, Johnson B, Kwiatkowski D, Iafrate AJ, Wistuba II, Aronson SL, al. e (2011) Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 29: 2011 (suppl; abstr CRA7506)
46. Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C (2014) The landscape of kinase fusions in cancer. Nat Commun 5:4846. doi:10.1038/ncomms5846
47. Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA, Hudis C, Chen D, Taran T, Hortobagyi G, Greene G, Berger M, Baselga J, Chandarlapaty S (2013) ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nature Gen 45(12):1439–1445. doi:10.1038/ng.2822
48. Merenbakh-Lamin K, Ben-Baruch N, Yeheskel A, Dvir A, Soussan-Gutman L, Jeselsohn R, Yelensky R, Brown M, Miller VA, Sarid D, Rizel S, Klein B, Rubinek T, Wolf I (2013) D538G mutation in estrogen receptor-alpha: a novel mechanism for acquired endocrine resistance in breast cancer. Cancer research 73(23):6856–6864. doi:10.1158/0008-5472.CAN-13-1197
49. Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, Kalyana-Sundaram S, Wang R, Ning Y, Hodges L, Gursky A, Siddiqui J, Tomlins SA, Roychowdhury S, Pienta KJ, Kim SY, Roberts JS, Rae JM, Van Poznak CH, Hayes DF, Chugh R, Kunju LP, Talpaz M, Schott AF, Chinnaiyan AM (2013) Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nature Gen 45(12):1446–1451. doi:10.1038/ng.2823
50. Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM, Ferrer-Lozano J, Perez-Fidalgo JA, Cristofanilli M, Gomez H, Arteaga CL, Giltnane J, Balko JM, Cronin MT, Jarosz M, Sun J, Hawryluk M, Lipson D, Otto G, Ross JS, Dvir A, Soussan-Gutman L, Wolf I, Rubinek T, Gilmore L, Schnitt S, Come SE, Pusztai L, Stephens P, Brown M, Miller VA (2014) Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res 20(7):1757–1767. doi:10.1158/1078-0432.CCR-13-2332
51. Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, He X, Liu S, Hoog J, Lu C, Ding L, Griffith OL, Miller C, Larson D, Fulton RS, Harrison M, Mooney T, McMichael JF, Luo J, Tao Y, Goncalves R, Schlosberg C, Hiken JF, Saied L, Sanchez C, Giuntoli T, Bumb C, Cooper C, Kitchens RT, Lin A, Phommaly C, Davies SR, Zhang J, Kavuri MS, McEachern D, Dong YY, Ma C, Pluard T, Naughton M, Bose R, Suresh R, McDowell R, Michel L, Aft R, Gillanders W, DeSchryver K, Wilson RK, Wang S, Mills GB, Gonzalez-Angulo A, Edwards JR, Maher C, Perou CM, Mardis ER, Ellis MJ (2013) Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep 4(6):1116–1130. doi:10.1016/j.celrep.2013.08.022
52. Knezevich SR, McFadden DE, Tao W, Lim JF, Sorensen PH (1998) A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nature Gen 18(2):184–187. doi:10.1038/ng0298-184
53. Knezevich SR, Garnett MJ, Pysher TJ, Beckwith JB, Grundy PE, Sorensen PH (1998) ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma. Cancer Res 58(22):5046–5048
54. Tognon C, Knezevich SR, Huntsman D, Roskelley CD, Melnyk N, Mathers JA, Becker L, Carneiro F, MacPherson N, Horsman D, Poremba C, Sorensen PH (2002) Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2(5):367–376
55. Makretsov N, He M, Hayes M, Chia S, Horsman DE, Sorensen PH, Huntsman DG (2004) A fluorescence in situ hybridization study of ETV6-NTRK3 fusion gene in secretory breast carcinoma. Genes Chromosomes Cancer 40(2):152–157. doi:10.1002/gcc.20028
56. Mano H (2008) Non-solid oncogenes in solid tumors: eML4-ALK fusion genes in lung cancer. Cancer Sci 99(12):2349–2355. doi:10.1111/j.1349-7006.2008.00972.x
57. Lin E, Li L, Guan Y, Soriano R, Rivers CS, Mohan S, Pandita A, Tang J, Modrusan Z (2009) Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res 7(9):1466–1476. doi:10.1158/1541-7786.MCR-08-0522
58. Fukuyoshi Y, Inoue H, Kita Y, Utsunomiya T, Ishida T, Mori M (2008) EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers. Br J cancer 98(9):1536–1539. doi:10.1038/sj.bjc.6604341
59. Grob TJ, Heilenkotter U, Geist S, Paluchowski P, Wilke C, Jaenicke F, Quaas A, Wilczak W, Choschzick M, Sauter G, Lebeau A (2012) Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer. Breast Cancer Res Treat 134(2):561–567. doi:10.1007/s10549-012-2092-7
60. Mosquera JM, Varma S, Pauli C, MacDonald TY, Yashinskie JJ, Varga Z, Sboner A, Moch H, Rubin MA, Shin SJ (2015) MAGI3-AKT3 fusion in breast cancer amended. Nature 520(7547):E11–E12. doi:10.1038/nature14265
61. Pugh TJ, Banerji S, Meyerson M (2015) Pugh et al. reply. Nature 520 (7547):E12-14. doi:10.1038/nature14266
62. Inaki K, Hillmer AM, Ukil L, Yao F, Woo XY, Vardy LA, Zawack KF, Lee CW, Ariyaratne PN, Chan YS, Desai KV, Bergh J, Hall P, Putti TC, Ong WL, Shahab A, Cacheux-Rataboul V, Karuturi RK, Sung WK, Ruan X, Bourque G, Ruan Y, Liu ET (2011) Transcriptional consequences of genomic structural aberrations in breast cancer. Gen Res 21(5):676–687. doi:10.1101/gr.113225.110
63. Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, Lonigro RJ, Vats P, Wang R, Lin SF, Cheng AJ, Kunju LP, Siddiqui J, Tomlins SA, Wyngaard P, Sadis S, Roychowdhury S, Hussain MH, Feng FY, Zalupski MM, Talpaz M, Pienta KJ, Rhodes DR, Robinson DR, Chinnaiyan AM (2013) Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov 3(6):636–647. doi:10.1158/2159-8290.CD-13-0050
64. Clay MR, Varma S, West RB (2013) MAST2 and NOTCH1 translocations in breast carcinoma and associated pre-invasive lesions. Hum Pathol 44(12):2837–2844. doi:10.1016/j.humpath.2013.08.001
65. Ren G, Zhang Y, Mao X, Liu X, Mercer E, Marzec J, Ding D, Jiao Y, Qiu Q, Sun Y, Zhang B, Yeste-Velasco M, Chelala C, Berney D, Lu YJ (2014) Transcription-mediated chimeric RNAs in prostate cancer: time to revisit old hypothesis? Omics: J Integr Biol 18(10):615–624. doi:10.1089/omi.2014.0042
66. Parra G, Reymond A, Dabbouseh N, Dermitzakis ET, Castelo R, Thomson TM, Antonarakis SE, Guigo R (2006) Tandem chimerism as a means to increase protein complexity in the human genome. Gen Res 16(1):37–44. doi:10.1101/gr.4145906
67. Varley KE, Gertz J, Roberts BS, Davis NS, Bowling KM, Kirby MK, Nesmith AS, Oliver PG, Grizzle WE, Forero A, Buchsbaum DJ, LoBuglio AF, Myers RM (2014) Recurrent read-through fusion transcripts in breast cancer. Breast Cancer Res Treat 146(2):287–297. doi:10.1007/s10549-014-3019-2
68. Nacu S, Yuan W, Kan Z, Bhatt D, Rivers CS, Stinson J, Peters BA, Modrusan Z, Jung K, Seshagiri S, Wu TD (2011) Deep RNA sequencing analysis of readthrough gene fusions in human prostate adenocarcinoma and reference samples. BMC Med Gen 4:11. doi:10.1186/1755-8794-4-11
69. Rickman DS, Pflueger D, Moss B, VanDoren VE, Chen CX, de la Taille A, Kuefer R, Tewari AK, Setlur SR, Demichelis F, Rubin MA (2009) SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. Cancer Res 69(7):2734–2738
70. Stoeck A, Lejnine S, Truong A, Pan L, Wang H, Zang C, Yuan J, Ware C, MacLean J, Garrett-Engele PW, Kluk M, Laskey J, Haines BB, Moskaluk C, Zawel L, Fawell S, Gilliland G, Zhang T, Kremer BE, Knoechel B, Bernstein BE, Pear WS, Liu XS, Aster JC, Sathyanarayanan S (2014) Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma. Cancer Discover 4(10):1154–1167. doi:10.1158/2159-8290.CD-13-0830
71. Li Z, Tognon CE, Godinho FJ, Yasaitis L, Hock H, Herschkowitz JI, Lannon CL, Cho E, Kim SJ, Bronson RT, Perou CM, Sorensen PH, Orkin SH (2007) ETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complex. Cancer Cell 12(6):542–558. doi:10.1016/j.ccr.2007.11.012
72. Rajadurai CV, Havrylov S, Zaoui K, Vaillancourt R, Stuible M, Naujokas M, Zuo D, Tremblay ML, Park M (2012) Met receptor tyrosine kinase signals through a cortactin-Gab1 scaffold complex, to mediate invadopodia. J Cell Sci 125(Pt 12):2940–2953. doi:10.1242/jcs.100834
73. Turnbull C, Ahmed S, Morrison J, Pernet D, Renwick A, Maranian M, Seal S, Ghoussaini M, Hines S, Healey CS, Hughes D, Warren-Perry M, Tapper W, Eccles D, Evans DG, Breast Cancer Susceptibility C, Hooning M, Schutte M, van den Ouweland A, Houlston R, Ross G, Langford C, Pharoah PD, Stratton MR, Dunning AM, Rahman N, Easton DF (2010) Genome-wide association study identifies five new breast cancer susceptibility loci. Nature Gen 42(6):504–507. doi:10.1038/ng.586
74. Wang Y, He Y, Qin Z, Jiang Y, Jin G, Ma H, Dai J, Chen J, Hu Z, Guan X, Shen H (2014) Evaluation of functional genetic variants at 6q25.1 and risk of breast cancer in a Chinese population. Breast Cancer Res 16(4):422. doi:10.1186/s13058-014-0422-x
75. Dunning AM, Michailidou K, Kuchenbaecker KB, Thompson D, French JD, Beesley J, Healey CS, Kar S, Pooley KA, Lopez-Knowles E, Dicks E, Barrowdale D, Sinnott-Armstrong NA, Sallari RC, Hillman KM, Kaufmann S, Sivakumaran H, Moradi Marjaneh M, Lee JS, Hills M, Jarosz M, Drury S, Canisius S, Bolla MK, Dennis J, Wang Q, Hopper JL, Southey MC, Broeks A, Schmidt MK, Lophatananon A, Muir K, Beckmann MW, Fasching PA, Dos-Santos-Silva I, Peto J, Sawyer EJ, Tomlinson I, Burwinkel B, Marme F, Guenel P, Truong T, Bojesen SE, Flyger H, Gonzalez-Neira A, Perez JI, Anton-Culver H, Eunjung L, Arndt V, Brenner H, Meindl A, Schmutzler RK, Brauch H, Hamann U, Aittomaki K, Blomqvist C, Ito H, Matsuo K, Bogdanova N, Dork T, Lindblom A, Margolin S, Kosma VM, Mannermaa A, Tseng CC, Wu AH, Lambrechts D, Wildiers H, Chang-Claude J, Rudolph A, Peterlongo P, Radice P, Olson JE, Giles GG, Milne RL, Haiman CA, Henderson BE, Goldberg MS, Teo SH, Yip CH, Nord S, Borresen-Dale AL, Kristensen V, Long J, Zheng W, Pylkas K, Winqvist R, Andrulis IL, Knight JA, Devilee P, Seynaeve C, Figueroa J, Sherman ME, Czene K, Darabi H, Hollestelle A, van den Ouweland AM, Humphreys K, Gao YT, Shu XO, Cox A, Cross SS, Blot W, Cai Q, Ghoussaini M, Perkins BJ, Shah M, Choi JY, Kang D, Lee SC, Hartman M, Kabisch M, Torres D, Jakubowska A, Lubinski J, Brennan P, Sangrajrang S, Ambrosone CB, Toland AE, Shen CY, Wu PE, Orr N, Swerdlow A, McGuffog L, Healey S, Lee A, Kapuscinski M, John EM, Terry MB, Daly MB, Goldgar DE, Buys SS, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Neuhausen SL, Ejlertsen B, Hansen TV, Osorio A, Benitez J, Rando R, Weitzel JN, Bonanni B, Peissel B, Manoukian S, Papi L, Ottini L, Konstantopoulou I, Apostolou P, Garber J, Rashid MU, Frost D, Embrace Izatt L, Ellis S, Godwin AK, Arnold N, Niederacher D, Rhiem K, Bogdanova-Markov N, Sagne C, Stoppa-Lyonnet D, Damiola F, Collaborators GS, Sinilnikova OM, Mazoyer S, Isaacs C, Claes KB, De Leeneer K, de la Hoya M, Caldes T, Nevanlinna H, Khan S, Mensenkamp AR, Hebon Hooning MJ, Rookus MA, Kwong A, Olah E, Diez O, Brunet J, Pujana MA, Gronwald J, Huzarski T, Barkardottir RB, Laframboise R, Soucy P, Montagna M, Agata S, Teixeira MR, kConFab I, Park SK, Lindor N, Couch FJ, Tischkowitz M, Foretova L, Vijai J, Offit K, Singer CF, Rappaport C, Phelan CM, Greene MH, Mai PL, Rennert G, Imyanitov EN, Hulick PJ, Phillips KA, Piedmonte M, Mulligan AM, Glendon G, Bojesen A, Thomassen M, Caligo MA, Yoon SY, Friedman E, Laitman Y, Borg A, von Wachenfeldt A, Ehrencrona H, Rantala J, Olopade OI, Ganz PA, Nussbaum RL, Gayther SA, Nathanson KL, Domchek SM, Arun BK, Mitchell G, Karlan BY, Lester J, Maskarinec G, Woolcott C, Scott C, Stone J, Apicella C, Tamimi R, Luben R, Khaw KT, Helland A, Haakensen V, Dowsett M, Pharoah PD, Simard J, Hall P, Garcia-Closas M, Vachon C, Chenevix-Trench G, Antoniou AC, Easton DF, Edwards SL (2016) Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature genetics 48(4):374–386. doi:10.1038/ng.3521
76. Ma CX, Reinert T, Chmielewska I, Ellis MJ (2015) Mechanisms of aromatase inhibitor resistance. Nature Rev Cancer 15(5):261–275. doi:10.1038/nrc3920
77. Weng AP, Ferrando AA, Lee W, Morris JPt, Silverman LB, Sanchez-Irizarry C, Blacklow SC, Look AT, Aster JC (2004) Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306(5694):269–271. doi:10.1126/science.1102160
78. Taipale M, Krykbaeva I, Whitesell L, Santagata S, Zhang J, Liu Q, Gray NS, Lindquist S (2013) Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells. Nature Biotechnol 31(7):630–637. doi:10.1038/nbt.2620
79. Ludes-Meyers JH, Liu Y, Munoz-Medellin D, Hilsenbeck SG, Brown PH (2001) AP-1 blockade inhibits the growth of normal and malignant breast cells. Oncogene 20(22):2771–2780. doi:10.1038/sj.onc.1204377
80. Benjamini Y, Speed TP (2012) Summarizing and correcting the GC content bias in high-throughput sequencing. Nucleic Acids Res 40(10):e72. doi:10.1093/nar/gks001
81. Natrajan R, Wilkerson PM, Marchio C, Piscuoglio S, Ng CK, Wai P, Lambros MB, Samartzis EP, Dedes KJ, Frankum J, Bajrami I, Kopec A, Mackay A, A’Hern R, Fenwick K, Kozarewa I, Hakas J, Mitsopoulos C, Hardisson D, Lord CJ, Kumar-Sinha C, Ashworth A, Weigelt B, Sapino A, Chinnaiyan AM, Maher CA, Reis-Filho JS (2014) Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. J Pathol 232(5):553–565. doi:10.1002/path.4325
82. Kim J, Kim S, Ko S, In YH, Moon HG, Ahn SK, Kim MK, Lee M, Hwang JH, Ju YS, Kim JI, Noh DY, Kim S, Park JH, Rhee H, Kim S, Han W (2015) Recurrent fusion transcripts detected by whole-transcriptome sequencing of 120 primary breast cancer samples. Genes Chromosomes Cancer 54(11):681–691. doi:10.1002/gcc.22279